NEWS - 2008

Interface Biologics Closes $5mm Financing and Appoints Thomas P. Reeves President and CEO

Toronto - December 9, 2008 - FOR IMMEDIATE RELEASE - Interface Biologics secures $5mm round of financing

Interface Biologics Inc. - a privately held developer of novel biomedical-polymers for use in implantable medical devices - is announcing that it has secured a $5mm financing round.

Endexo Shows Equivalent Efficacy to Commercial Heparinized Coatings

Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings.

In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin coated catheters, both products achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane ^TM) control (data on file).

Endexo Surfaces provide Anti-thrombic Effect without Heparin

Medical device manufacturers are seeking alternatives to contaminated heparin coatings used to prevent thrombus in medical devices.